Chinese IPO activity on the rise since 2019 reforms

Research from industry analyst GlobalData shows that initial public offerings (IPO) of Chinese biotech and pharma companies have increased since key reforms were introduced in 2019.

Oncology remains the top therapy area for such companies going public in China, following a set of reforms which included a pilot registration-based system for capital markets.

Associate director Sharon Cartic said: “Chinese oncology therapeutic companies showed a 150% increase in the number of IPO deals from 2019 to 2020 compared to other therapy areas.”